Literature DB >> 7815511

Induction of protective cytotoxic T cells to murine cytomegalovirus by using a nonapeptide and a human-compatible adjuvant (Montanide ISA 720).

A A Scalzo1, S L Elliott, J Cox, J Gardner, D J Moss, A Suhrbier.   

Abstract

The use of synthetic peptides representing cytotoxic T-cell (CTL) epitopes for human vaccination requires the identification of a suitable adjuvant formulation. A single immunization with Montanide ISA720/tetanus toxoid/YPHFMPTNL protected mice against murine cytomegalovirus and induced epitope-specific CTL. Such formulations will find application in peptide-based CTL anti-viral vaccines.

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7815511      PMCID： PMC188710     

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  31 in total

1.  Subjugation of dominant immunogenic determinants within a chimeric peptide.

Authors:  V Bhardwaj; V Kumar; H M Geysen; E E Sercarz
Journal:  Eur J Immunol       Date:  1992-08       Impact factor: 5.532

Review 2.  Synthetic peptides as vaccines.

Authors:  R Arnon; R J Horwitz
Journal:  Curr Opin Immunol       Date:  1992-08       Impact factor: 7.486

Review 3.  Adjuvants: current status, clinical perspectives and future prospects.

Authors:  F M Audibert; L D Lise
Journal:  Immunol Today       Date:  1993-06

4.  Herpes simplex virus class I-restricted peptide induces cytotoxic T lymphocytes in vivo independent of CD4+ T cells.

Authors:  J P Vasilakos; J G Michael
Journal:  J Immunol       Date:  1993-03-15       Impact factor: 5.422

5.  Iscom immunization with synthetic peptides representing measles virus hemagglutinin.

Authors:  I R Pedersen; T C Bøg-Hansen; K Dalsgaard; P M Heegaard
Journal:  Virus Res       Date:  1992-07       Impact factor: 3.303

6.  T helper epitopes enhance the cytotoxic response of mice immunized with MHC class I-restricted malaria peptides.

Authors:  C Widmann; P Romero; J L Maryanski; G Corradin; D Valmori
Journal:  J Immunol Methods       Date:  1992-10-19       Impact factor: 2.303

7.  Heterologous protection against influenza by injection of DNA encoding a viral protein.

Authors:  J B Ulmer; J J Donnelly; S E Parker; G H Rhodes; P L Felgner; V J Dwarki; S H Gromkowski; R R Deck; C M DeWitt; A Friedman
Journal:  Science       Date:  1993-03-19       Impact factor: 47.728

Review 8.  Adjuvants--a balance between toxicity and adjuvanticity.

Authors:  R K Gupta; E H Relyveld; E B Lindblad; B Bizzini; S Ben-Efraim; C K Gupta
Journal:  Vaccine       Date:  1993       Impact factor: 3.641

9.  Mechanisms of mouse spleen dendritic cell function in the generation of influenza-specific, cytolytic T lymphocytes.

Authors:  R Nonacs; C Humborg; J P Tam; R M Steinman
Journal:  J Exp Med       Date:  1992-08-01       Impact factor: 14.307

10.  A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E.

Authors:  C Traversari; P van der Bruggen; I F Luescher; C Lurquin; P Chomez; A Van Pel; E De Plaen; A Amar-Costesec; T Boon
Journal:  J Exp Med       Date:  1992-11-01       Impact factor: 14.307
View more
  12 in total

Review 1.  Clinically feasible approaches to potentiating cancer cell-based immunotherapies.

Authors:  V I Seledtsov; A G Goncharov; G V Seledtsova
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

2.  Long term stability of a recombinant Plasmodium falciparum AMA1 malaria vaccine adjuvanted with Montanide(®) ISA 720 and stabilized with glycine.

Authors:  Daming Zhu; Holly McClellan; Weili Dai; Elizabeth Gebregeorgis; Mary Anne Kidwell; Joan Aebig; Kelly M Rausch; Laura B Martin; Ruth D Ellis; Louis Miller; Yimin Wu
Journal:  Vaccine       Date:  2011-04-08       Impact factor: 3.641

3.  Alphavirus-specific cytotoxic T lymphocytes recognize a cross-reactive epitope from the capsid protein and can eliminate virus from persistently infected macrophages.

Authors:  M L Linn; L Mateo; J Gardner; A Suhrbier
Journal:  J Virol       Date:  1998-06       Impact factor: 5.103

4.  Highly protective in vivo function of cytomegalovirus IE1 epitope-specific memory CD8 T cells purified by T-cell receptor-based cell sorting.

Authors:  Marcus-Folker Pahl-Seibert; Markus Juelch; Jürgen Podlech; Doris Thomas; Petra Deegen; Matthias J Reddehase; Rafaela Holtappels
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

5.  Suppression of murine cytomegalovirus (MCMV) replication with a DNA vaccine encoding MCMV M84 (a homolog of human cytomegalovirus pp65).

Authors:  C S Morello; L D Cranmer; D H Spector
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

6.  Induction of long-term memory CD8(+) T cells for recall of viral clearing responses against influenza virus.

Authors:  Georgia Deliyannis; David C Jackson; Nicholas J Ede; Weiguang Zeng; Irene Hourdakis; Evaline Sakabetis; Lorena E Brown
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

7.  Mucosal and parenteral vaccination against acute and latent murine cytomegalovirus (MCMV) infection by using an attenuated MCMV mutant.

Authors:  M R MacDonald; X Y Li; R M Stenberg; A E Campbell; H W Virgin
Journal:  J Virol       Date:  1998-01       Impact factor: 5.103

8.  Phase I trial of a CD8+ T-cell peptide epitope-based vaccine for infectious mononucleosis.

Authors:  Suzanne L Elliott; Andreas Suhrbier; John J Miles; Greg Lawrence; Stephanie J Pye; Thuy T Le; Andrew Rosenstengel; Tam Nguyen; Anthony Allworth; Scott R Burrows; John Cox; David Pye; Denis J Moss; Mandvi Bharadwaj
Journal:  J Virol       Date:  2007-11-21       Impact factor: 5.103

Review 9.  A fifty-year odyssey: prospects for a cytomegalovirus vaccine in transplant and congenital infection.

Authors:  Don Jeffrey Diamond; Corinna La Rosa; Flavia Chiuppesi; Heidi Contreras; Sanjeet Dadwal; Felix Wussow; Supriya Bautista; Ryotaro Nakamura; John A Zaia
Journal:  Expert Rev Vaccines       Date:  2018-10-03       Impact factor: 5.217

10.  Intratumoral checkpoint subversion as a strategy for minimizing adverse effects: Harvesting the power of TILs without harvesting TILs.

Authors:  Leah Alabanza; Sacha Gnjatic; Nina Bhardwaj; Joshua Brody
Journal:  Oncoimmunology       Date:  2014-01-03       Impact factor: 8.110
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.